Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies

AAPS Journal

Volumn 19, Issue 5, 2017, Pages 1499-1512

  Tsamandouras, Nikolaos ^a   Chen, Wen Li Kelly ^a   Edington, Collin D ^a   Stokes, Cynthia L ^b   Griffith, Linda G ^a   Cirit, Murat ^a  

^a Massachusetts Institute of Technology   (United States)

^b Stokes Consulting   (United States)

Author keywords

drug development; gut liver integration; microphysiological systems; organs on chips; pharmacokinetics

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; DICLOFENAC; HYDROCORTISONE;

ARTICLE; CELL CULTURE TECHNIQUE; COCULTURE; DISTRIBUTION PARAMETERS; DRUG METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTESTINE; INTESTINE MUCOSA PERMEABILITY; LIVER; LIVER METABOLISM; METABOLIC CLEARANCE; METABOLIC REGULATION; MICROFLUIDICS; MICROPHYSIOLOGICAL SYSTEM; PHARMACOKINETICS; PHENOTYPE; QUANTITATIVE STUDY; TISSUE SPECIFICITY; UPREGULATION; METABOLISM;

DICLOFENAC; HUMANS; HYDROCORTISONE; IN VITRO TECHNIQUES; INTESTINES; LIVER;

EID: 85026905814     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-017-0122-4     Document Type: Article

References (55)

1. Zhang D, Luo G, Ding X, Lu C. Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharm Sin B. 2012;2(6):549–61.
2. Sutherland ML, Fabre KM, Tagle DA. The national institutes of health microphysiological systems program focuses on a critical challenge in the drug discovery pipeline. Stem Cell Res Ther. 2013;4(1):I1.
3. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–72.
4. Esch EW, Bahinski A, Huh D. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov. 2015;14(4):248–60.
5. Nam KH, Smith AS, Lone S, Kwon S, Kim DH. Biomimetic 3D tissue models for advanced high-throughput drug screening. J Lab Autom. 2015;20(3):201–15.
6. Vivares A, Salle-Lefort S, Arabeyre-Fabre C, Ngo R, Penarier G, Bremond M, et al. Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device. Xenobiotica. 2015;45(1):29–44.
7. Ouattara DA, Choi S-H, Sakai Y, Péry ARR, Brochot C. Kinetic modelling of in vitro cell-based assays to characterize non-specific bindings and ADME processes in a static and a perfused fluidic system. Toxicol Lett. 2011;205(3):310–9.
8. Ebrahimkhani MR, Neiman JAS, Raredon MSB, Hughes DJ, Griffith LG. Bioreactor technologies to support liver function in vitro. Adv Drug Deliv Rev. 2014;69–70:132–57.
9. Zheng F, Fu F, Cheng Y, Wang C, Zhao Y, Gu Z. Organ-on-a-chip systems: microengineering to biomimic living systems. Small. 2016;12(17):2253–82.
10. Sung JH, Shuler ML. A micro cell culture analog ([small micro]cca) with 3-d hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip. 2009;9(10):1385–94.
11. Oleaga C, Bernabini C, Smith AS, Srinivasan B, Jackson M, McLamb W, et al. Multi-organ toxicity demonstration in a functional human in vitro system composed of four organs. Sci Rep. 2016;6:20030.
12. Maschmeyer I, Lorenz AK, Schimek K, Hasenberg T, Ramme AP, Hubner J, et al. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab Chip. 2015;15(12):2688–99.
13. Materne EM, Maschmeyer I, Lorenz AK, Horland R, Schimek KM, Busek M, et al. The multi-organ chip—a microfluidic platform for long-term multi-tissue coculture. J Vis Exp. 2015;98:e52526.
14. Esch MB, Mahler GJ, Stokol T, Shuler ML. Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. Lab Chip. 2014;14(16):3081–92.
15. Sin A, Chin KC, Jamil MF, Kostov Y, Rao G, Shuler ML. The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors. Biotechnol Prog. 2004;20(1):338–45.
16. Viravaidya K, Sin A, Shuler ML. Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol Prog. 2004;20(1):316–23.
17. Sung JH, Kam C, Shuler ML. A microfluidic device for a pharmacokinetic-pharmacodynamic (pk-pd) model on a chip. Lab Chip. 2010;10(4):446–55.
18. Esch MB, Ueno H, Applegate DR, Shuler ML. Modular, pumpless body-on-a-chip platform for the co-culture of GI tract epithelium and 3D primary liver tissue. Lab Chip. 2016;16(14):2719–29.
19. Maschmeyer I, Hasenberg T, Jaenicke A, Lindner M, Lorenz AK, Zech J, et al. Chip-based human liver-intestine and liver-skin co-cultures—a first step toward systemic repeated dose substance testing in vitro. Eur J Pharm Biopharm. 2015;95(Pt A):77–87.
20. Prot JM, Maciel L, Bricks T, Merlier F, Cotton J, Paullier P, et al. First pass intestinal and liver metabolism of paracetamol in a microfluidic platform coupled with a mathematical modeling as a means of evaluating ADME processes in humans. Biotechnol Bioeng. 2014;111(10):2027–40.
21. Imura Y, Yoshimura E, Sato K. Micro total bioassay system for oral drugs: evaluation of gastrointestinal degradation, intestinal absorption, hepatic metabolism, and bioactivity. Anal Sci. 2012;28(3):197–9.
22. Kimura H, Ikeda T, Nakayama H, Sakai Y, Fujii T. An on-chip small intestine-liver model for pharmacokinetic studies. J Lab Autom. 2015;20(3):265–73.
23. Jie M, Li H-F, Lin L, Zhang J, Lin J-M. Integrated microfluidic system for cell co-culture and simulation of drug metabolism. RSC Adv. 2016;6(59):54564–72.
24. Tsamandouras N, Kostrzewski T, Stokes CL, Griffith LG, Hughes DJ, Cirit M. Quantitative assessment of population variability in hepatic drug metabolism using a perfused three-dimensional human liver microphysiological system. J Pharmacol Exp Ther. 2017;360(1):95–105.
25. Sarkar U, Rivera-Burgos D, Large EM, Hughes DJ, Ravindra KC, Dyer RL, et al. Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. Drug Metab Dispos. 2015;43(7):1091–9.
26. Long TJ, Cosgrove PA, Dunn RT, Stolz DB, Hamadeh HK, Afshari C, et al. Modeling therapeutic antibody-small molecule drug-drug interactions using a 3D perfusable human liver co-culture platform. Drug Metab Dispos. 2016;44(12):1940–8.
27. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health. 1997;13(4):407–84.
28. Yu J, Cilfone NA, Large EM, Sarkar U, Wishnok JS, Tannenbaum SR, et al. Quantitative systems pharmacology approaches applied to microphysiological systems (MPS): data interpretation and multi-MPS integration. CPT Pharmacometrics Syst Pharmacol. 2015;4(10):585–94.
29. Domansky K, Inman W, Serdy J, Dash A, Lim MHM, Griffith LG. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip. 2010;10(1):51–8.
30. Chen WLK, Edington C, Suter E, Yu J, Velazquez JJ, Velazquez JG, et al. Integrated gut/liver microphysiological systems elucidates inflammatory inter-tissue crosstalk. Biotechnol Bioeng. 2017; doi:10.1002/bit.26370.
31. Sarkar U, Ravindra KC, Large E, Young CL, Rivera-Burgos D, Yu J, et al. Integrated assessment of diclofenac biotransformation, pharmacokinetics, and omics-based toxicity in a three-dimensional human liver-immunocompetent coculture system. Drug Metab Dispos. 2017;45(7):855–66.
32. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet. 1997;33(3):184–213.
33. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7(4):457–72.
34. Plummer M, Best N, Cowles K, Vines K. Coda: convergence diagnosis and output analysis for MCMC. R News. 2006;6(1):7–11.
35. Gelman A. Inference and monitoring convergence, Markov chain monte carlo in practice. Boca Raton: Chapman & Hall; 1996. p. 131–43.
36. Stokes CL, Cirit M, Lauffenburger DA. Physiome-on-a-chip: the challenge of “scaling” in design, operation, and translation of microphysiological systems. CPT Pharmacometrics Syst Pharmacol. 2015;4(10):559–62.
37. Fabre KM, Livingston C, Tagle DA. Organs-on-chips (microphysiological systems): tools to expedite efficacy and toxicity testing in human tissue. Exp Biol Med. 2014;239(9):1073–7.
38. Toepke MW, Beebe DJ. PDMS absorption of small molecules and consequences in microfluidic applications. Lab Chip. 2006;6(12):1484–6.
39. Low LA, Tagle DA. Microphysiological systems (“organs-on-chips”) for drug efficacy and toxicity testing. Clin Transl Sci 2017.
40. Ng S-F, Rouse J, Sanderson D, Eccleston G. A comparative study of transmembrane diffusion and permeation of ibuprofen across synthetic membranes using franz diffusion cells. Pharmaceutics. 2010;2(2):209–23.
41. Mahler GJ, Esch MB, Tako E, Southard TL, Archer SD, Glahn RP, et al. Oral exposure to polystyrene nanoparticles affects iron absorption. Nat Nanotechnol. 2012;7(4):264–71.
42. Nollevaux G, Devillé C, El Moualij B, Zorzi W, Deloyer P, Schneider Y-J, et al. Development of a serum-free co-culture of human intestinal epithelium cell-lines (Caco-2/HT29-5M21). BMC Cell Biol. 2006;7:20.
43. VanDussen KL, Marinshaw JM, Shaikh N, Miyoshi H, Moon C, Tarr PI, et al. Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays. Gut. 2015;64(6):911–20.
44. Paixão P, Gouveia LF, Morais JAG. Prediction of the in vitro permeability determined in Caco-2 cells by using artificial neural networks. Eur J Pharm Sci. 2010;41(1):107–17.
45. Mateus A, Matsson P, Artursson P. Rapid measurement of intracellular unbound drug concentrations. Mol Pharm. 2013;10(6):2467–78.
46. Wikswo JP, Curtis EL, Eagleton ZE, Evans BC, Kole A, Hofmeister LH, et al. Scaling and systems biology for integrating multiple organs-on-a-chip. Lab Chip. 2013;13(18):3496–511.
47. Ucciferri N, Sbrana T, Ahluwalia A. Allometric scaling and cell ratios in multi-organ in vitro models of human metabolism. Front Bioeng Biotechnol. 2014;2(74).
48. Abaci HE, Shuler ML. Human-on-a-chip design strategies and principles for physiologically based pharmacokinetics/pharmacodynamics modeling. Integr Biol. 2015;7(4):383–91.
49. Maass C, Stokes CL, Griffith LG, Cirit M. Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS). Integr Biol. 2017;9(4):290–302.
50. Noah TK, Donahue B, Shroyer NF. Intestinal development and differentiation. Exp Cell Res. 2011;317(19):2702–10.
51. Helander HF, Fandriks L. Surface area of the digestive tract—revisited. Scand J Gastroenterol. 2014;49(6):681–9.
52. Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, et al. Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res. 2006;23(3):533–9.
53. Hallifax D, Foster JA, Houston JB. Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res. 2010;27(10):2150–61.
54. Galetin A. Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling. In: Nagar S, Argikar AU, Tweedie JD, editors. Enzyme kinetics in drug metabolism: fundamentals and applications. Totowa: Humana Press; 2014. p. 255–88.
55. Bowman CM, Benet LZ. Hepatic clearance predictions from in vitro-in vivo extrapolation and BDDCS. Drug Metab Dispos. 2016;44(11):1731–5.